natgillin/translations-raw huggingface dataset:
Hver Lamictal 100 mg dispergibel tablet / tyggetabletindeholder 100 mg lamotrigin.
Each Lamictal 100 mg dispersible/ chewable tablet contains 100 mg lamotrigine.
Hver Lamictal 200 mg dispergibel tablet / tyggetabletindeholder 200 mg lamotrigin.
Each Lamictal 200 mg dispersible/ chewable tablet contains 200 mg lamotrigine.
Dispergibel tablet / tyggetablet.
Dispersible/ chewable tablet.
Lys, gulligbrun, multifacetslebet, superellipseformet tablet påtrykt "GS EC7" på den ene side og "25" på den anden side.
Pale, yellowish-brown, multifaceted, super-elliptical tablet, marked “ GSEC7” on one side and “ 25” on the other.
Lys, gulligbrun, multifacetslebet, superellipseformet tablet påtrykt "GS EE1" på den ene side og "50" på den anden side.
Pale, yellowish-brown, multifaceted, super-elliptical tablet, marked “ GSEE1” on one side and “ 50” on the other.
Lys, gulligbrun, multifacetslebet, superellipseformet tablet påtrykt "GS EE5" på den ene side og "100" på den anden side.
Pale, yellowish-brown, multifaceted, super-elliptical tablet, marked “ GSEE5” on one side and “ 100” on the other.
48 200 mg tabletter:
47 200 mg tablets:
Lys, gulligbrun, multifacetslebet, superellipseformet tablet påtrykt "GS EE7" på den ene side og "200" på den anden side.
Pale, yellowish-brown, multifaceted, super-elliptical tablet, marked “ GSEE7” on one side and “ 200” on the other.
2 mg dispergible tabletter / tyggetabletter:
2 mg dispersible/ chewable tablets:
Den ene side har en skrå kant og er påtrykt "LTG" over tallet 2.
One side has a bevelled edge and is marked “ LTG” above the number 2.
5 mg dispergible tabletter / tyggetabletter:
5 mg dispersible/ chewable tablets:
Hvid til offwhite, aflang, bikonveks tablet med solbærlugt påtrykt "GS CL2" på den ene side og "5" på den anden side.
White to off-white, elongated, biconvex tablet with a blackcurrant odour, marked “ GS CL2” on one side and “ 5” on the other.
25 mg dispergible tabletter / tyggetabletter:
25 mg dispersible/ chewable tablets:
Hvid til offwhite, multifacetslebet, superellipseformet tablet med solbærlugt påtrykt "GS CL5" på den ene side og "25" på den anden side.
White to off-white multi-faceted, super-elliptical, tablet with a blackcurrant odour, marked “ GSCL5” on one side “ 25” on the other.
50 mg dispergible tabletter / tyggetabletter:
50 mg dispersible/ chewable tablets:
Hvid til offwhite, multifacetslebet, superellipseformet tablet med solbærlugt påtrykt "GS CX7" på den ene side og "50" på den anden side.
White to off-white multi-faceted, super-elliptical, tablet with a blackcurrant odour, marked “ GSCX7” on one side and “ 50” on the other.
100 mg dispergible tabletter / tyggetabletter:
100 mg dispersible/ chewable tablets:
Hvid til offwhite, multifacetslebet, superellipseformet tablet med solbærlugt påtrykt "GS CL7" på den ene side og "100" på den anden side.
White to off-white multi-faceted, super-elliptical, tablet with a blackcurrant odour, marked “ GSCL7” on one side and “ 100” on the other.
200 mg dispergible tabletter / tyggetabletter:
200 mg dispersible/ chewable tablets:
Hvid til offwhite, multifacetslebet, superellipseformet tablet med solbærlugt påtrykt "GS EC5" på den ene side og "200" på den anden side.
White to off-white multi-faceted, super-elliptical, tablet with a blackcurrant odour, marked “ GSEC5” on one side and “ 200” on the other.
Voksne og unge i alderen 13 år og derover
Adults and adolescents aged 13 years and above
- Monoterapi eller tillægsbehandling af epilepsi med partielle og generaliserede anfald, herunder
- Adjunctive or monotherapy treatment of partial seizures and generalised seizures, including
- Anfald associeret med Lennox- Gastaut- syndrom.
- Seizures associated with Lennox-Gastaut syndrome.
Lamictal gives som tillægsbehandling, men
Lamictal is given as adjunctive therapy
kan være den første antiepileptika til at starte med ved Lennox- Gastaut syndrom.
but may be the initial antiepileptic drug (AED) to start with in Lennox-Gastaut syndrome.
Børn og unge i alderen 2- 12 år
Children and adolescents aged 2 to 12 years
- Tillægsbehandling af epilepsi med partielle og generaliserede anfald, herunder tonisk- kloniske
- Adjunctive treatment of partial seizures and generalised seizures, including tonic-clonic
anfald og anfald associeret med Lennox- Gastaut- syndrom.
seizures and the seizures associated with Lennox-Gastaut syndrome.
Voksne i alderen 18 år og derover
Adults aged 18 years and above
- Forebyggelse af depressive episoder hos patienter med bipolar sygdom af type I, der primært
- Prevention of depressive episodes in patients with bipolar I disorder who experience
5. 1).
predominantly depressive episodes (see section 5.1).
49 4. 2 Dosering og indgivelsesmåde
48 4.2 Posology and method of administration
Lamictal- tabletterne skal synkes hele og må ikke tygges eller knuses.
Lamictal tablets should be swallowed whole, and should not be chewed or crushed.
Lamictal dispergible tabletter / tyggetabletter kan tygges, dispergeres i en lille smule vand (nok til at dække hele tabletten) eller synkes hele med lidt vand.
Lamictal dispersible/ chewable tablets may be chewed, dispersed in a small volume of water (at least enough to cover the whole tablet) or swallowed whole with a little water.
Hvis den beregnede dosis lamotrigin (f. eks. til behandling af børn med epilepsi eller patienter med nedsat leverfunktion) ikke svarer til et helt antal tabletter, skal den anvendte dosis svare til laveste antal hele tabletter.
If the calculated dose of lamotrigine (for example for treatment of children with epilepsy or patients with hepatic impairment) does not equate to whole tablets, the dose to be administered is that equal to the lower number of whole tablets.
Genstart af behandling
Restarting therapy
4. 4).
Prescribers should assess the need for escalation to maintenance dose when restarting Lamictal in patients who have discontinued Lamictal for any reason, since the risk of serious rash is associated with high initial doses and exceeding the recommended dose escalation for lamotrigine (see section 4.4).
5. 2) siden seponeringen af lamotrigin, skal dosis af Lamictal normalt øges til vedligeholdelsesdosis i henhold til den relevante optrapningsplan.
When the interval since discontinuing lamotrigine exceeds five half-lives (see section 5.2), Lamictal should generally be escalated to the maintenance dose according to the appropriate schedule.
Det frarådes at genstarte behandlingen med Lamictal hos patienter, som er ophørt på grund af udslæt, der er forbundet med tidligere behandling med lamotrigin, medmindre den mulige fordel klart opvejer risikoen.
It is recommended that Lamictal not be restarted in patients who have discontinued due to rash associated with prior treatment with lamotrigine unless the potential benefit clearly outweighs the risk.
Den anbefalede dosisøgning og de anbefalede vedligeholdelsesdoser til voksne og unge i alderen 13 år og derover (tabel 1) og til børn i alderen 2- 12 år (tabel 2) er angivet nedenfor.
The recommended dose escalation and maintenance doses for adults and adolescents aged 13 years and above (Table 1) and for children and adolescents aged 2 to 12 years (Table 2) are given below.
4. 4).
Because of a risk of rash the initial dose and subsequent dose escalation should not be exceeded (see section 4.4).
4. 5).
When concomitant AEDs are withdrawn or other AEDs/ medicinal products are added on to treatment regimes containing lamotrigine, consideration should be given to the effect this may have on lamotrigine pharmacokinetics (see section 4.5).
50 Tabel 1:
49 Table 1:
Voksne og unge i alderen 13 år og derover – anbefalet behandlingsregimen ved epilepsi
Adults and adolescents aged 13 years and above – recommended treatment regimen in epilepsy
Uge 1 + 2
Weeks 1 + 2
Uge 3 + 4
Weeks 3 + 4
Normal vedligeholdelsesdosis
Usual maintenance dose
25 mg/ dag (én gang dagligt)
25 mg/ day (once a day)
50 mg/ dag (én gang dagligt)
50 mg/ day (once a day)
100- 200 mg/ dag (én gang dagligt eller fordelt på to doser) For at nå vedligeholdelsesdosis må doserne maksimalt øges med 50- 100 mg hver eller hver anden uge, indtil den optimale respons er opnået
100 − 200 mg/ day (once a day or two divided doses)
Nogle patienter har haft behov for 500 mg/ dag for at opnå den ønskede respons
500 mg/ day has been required by some patients to achieve desired response
4. 5):
Adjunctive therapy WITH valproate (inhibitor of lamotrigine glucuronidation – see section 4.5):
Dette dosisregimen skal kombineres med valproat,
This dosage regimen
12, 5 mg/ dag (administreret
12.5 mg/ day
25 mg/ dag (én gang
25 mg/ day
100- 200 mg/ dag (én gang dagligt eller fordelt på to doser)
100 − 200 mg/ day
uanset om der administreres som 25 mg hver dagligt) andre lægemidler samtidigt anden dag)
(given as 25 mg (once a day) on alternate
For at nå vedligeholdelsesdosis må doserne maksimalt øges med 25- 50 mg hver eller hver anden uge, indtil den optimale respons er opnået
(once a day or two divided doses)
4. 5):
Adjunctive therapy WITHOUT valproate and WITH inducers of lamotrigine glucuronidation (see section 4.5):
Dette dosisregimen skal ikke kombineres med valproat, men med:
This dosage regimen should be used without valproate but with:
100 mg/ dag (fordelt på to doser)
100 mg/ day (two divided doses)
200- 400 mg/ dag (fordelt på to doser) For at nå vedligeholdelsesdosis må
200 − 400 mg/ day (two divided doses) To achieve maintenance, doses may be
phenytoin carbamazepin phenobarbital primidon
phenytoin carbamazepine phenobarbitone primidone
doserne maksimalt øges med 100 mg hver eller hver anden uge, indtil den optimale respons er opnået
increased by maximum of 100 mg every one to two weeks until optimal response is achieved
rifampicin lopinavir/ ritonavir
rifampicin lopinavir/ ritonavir
Nogle patienter har haft behov for 700 mg/ dag for at opnå den ønskede respons
700 mg/ day has been required by some patients to achieve desired response
4. 5):
Adjunctive therapy WITHOUT valproate and WITHOUT inducers of lamotrigine glucuronidation (see section 4.5):
Dette dosisregimen skal kombineres med andre lægemidler, der ikke signifikant hæmmer eller inducerer glukuronidering af lamotrigin
This dosage regimen should be used with other medicinal products that do
Hos patienter, der tager lægemidler, hvor den farmakokinetiske interaktion med lamotrigin ikke kendes på nuværende tidspunkt (se pkt.
not significantly inhibit or induce lamotrigine glucuronidation
4. 5), skal der anvendes det behandlingsregimen, som anbefales for lamotrigin i kombination med valproat.
In patients taking medicinal products where the pharmacokinetic interaction with lamotrigine is currently not known (see section 4.5), the treatment regimen as recommended for lamotrigine with concurrent valproate should be used.
51 Tabel 2:
50 Table 2:
Børn og unge i alderen 2- 12 år – anbefalet behandlingsregimen ved epilepsi (samlet daglig dosis i mg/ kg legemsvægt/ dag)
Children and adolescents aged 2 to 12 years - recommended treatment regimen in epilepsy (total daily dose in mg/ kg body weight/ day)
0, 3 mg/ kg/ dag (én gang dagligt eller fordelt på to doser)
0.3 mg/ kg/ day (once a day or two divided doses)
0, 6 mg/ kg/ dag (én gang dagligt eller fordelt på to doser)
0.6 mg/ kg/ day (once a day or two divided doses)
1- 10 mg/ kg/ dag, selvom nogle patienter har haft behov for højere doser (op til 15 mg/ kg/ dag) for at opnå den ønskede respons (én gang dagligt eller fordelt på to doser)
1 – 10 mg/ kg/ day, although some patients have required higher doses (up to 15 mg/ kg/ day) to achieve desired response (once a day or two divided doses)
4. 5):
To achieve maintenance, doses may be increased by maximum of 0.6 mg/ kg/ day every one to two weeks until optimal response is achieved Adjunctive therapy WITH valproate (inhibitor of lamotrigine glucuronidation – see section 4.5):
Dette dosisregimen skal ikke kombineres med valproat, men med:
This dosage regimen should be used with valproate regardless of any
0, 6 mg/ kg/ dag (fordelt på to doser)
0.15 mg/ kg/ day* 0.3 mg/ kg/ day 1 − (once a day) (once a day)
1, 2 mg/ kg/ dag 5- 15 mg/ kg/ dag (fordelt på to (én gang dagligt eller fordelt på to doser) doser) For at nå vedligeholdelsesdosis må
5 mg/ kg/ day (once a day or two divided doses)
phenytoin carbamazepin phenobarbital primidon rifampicin lopinavir/ ritonavir
other concomitant medicinal products
doserne maksimalt øges med 1, 2 mg/ kg hver eller hver anden uge, indtil den optimale respons er opnået, og vedligeholdelsesdosis må maksimalt være 400 mg/ dag
To achieve maintenance, doses may be increased by maximum of 0.3 mg/ kg every one to two weeks until optimal response is achieved, with a maximum maintenance dose of 200 mg/ day
Tillægsbehandling UDEN valproat og UDEN induktorer af lamotrigin- glukuronidering (se pkt.
Adjunctive therapy WITHOUT valproate and WITH inducers of lamotrigine glucuronidation (see section 4.5):
Dette dosisregimen skal
This dosage regimen should be used without valproate but with:
0, 3 mg/ kg/ dag
0.6 mg/ kg/ day (two divided doses)
0, 6 mg/ kg/ dag 1- 10 mg/ kg/ dag
1.2 mg/ kg/ day 5 − 15 mg/ kg/ day (two divided (once a day or two divided doses) doses) To achieve maintenance, doses may be
kombineres med andre lægemidler, der ikke
phenytoin carbamazepine phenobarbitone primidone rifampicin lopinavir/ ritonavir
(én gang dagligt (én gang eller fordelt på dagligt eller
increased by maximum of 1.2 mg/ kg every one to two weeks until optimal response is achieved, with a maximum maintenance dose of 400 mg/ day
(én gang dagligt eller fordelt på to doser)
Adjunctive therapy WITHOUT valproate and WITHOUT inducers of lamotrigine glucuronidation (see section 4.5):
signifikant hæmmer eller inducerer glukuronidering af lamotrigin
This dosage regimen should be used with other medicinal products that do not significantly inhibit or induce lamotrigine glucuronidation
to doser) fordelt på to doser)
0.3 mg/ kg/ day (once a day or two divided doses)
For at nå vedligeholdelsesdosis må doserne maksimalt øges med 0, 6 mg/ kg hver eller hver anden uge, indtil den optimale respons er opnået, og vedligeholdelsesdosis må maksimalt være 200 mg/ dag
0.6 mg/ kg/ day 1 − 10 mg/ kg/ day (once a day or (once a day or two divided doses) two divided doses) To achieve maintenance, doses may be increased by maximum of 0.6 mg/ kg every one to two weeks until optimal response is achieved, with a maximum of maintenance dose of 200 mg/ day
2 mg dispergible tabletter / tyggetabletter – hvor dette er den laveste markedsførte styrke: * Hvis den beregnede daglige dosis til patienter, der tager valproat, er 1 mg eller derover, men under 2 mg, kan der tages Lamictal 2 mg dispergible tabletter / tyggetabletter hver anden dag i de første to uger.
2 mg dispersible/ chewable tablets - where this is the lowest marketed strength: < * If the calculated daily dose in patients taking valproate is 1 mg or more but less than 2 mg, then Lamictal 2 mg dispersible/ chewable tablets may be taken on alternate days for the first two weeks.
Hvis den beregnede daglige dosis til patienter, der tager valproat, er lavere end 1 mg, må der ikke administreres Lamictal.
If the calculated daily dose in patients taking valproate is less than 1 mg, then Lamictal should not be administered. >
52 5 mg dispergible tabletter / tyggetabletter – hvor 2 mg dispergible tabletter / tyggetabletter ikke er markedsført, og Lamictal 5 mg dispergible tabletter / tyggetabletter er den laveste markedsførte styrke: * Hvis den beregnede daglige dosis til patienter, der tager valproat, er 2, 5 mg eller derover, men under 5 mg, kan der tages Lamictal 5 mg dispergible tabletter / tyggetabletter hver anden dag i de første to uger.
51 5 mg dispersible/ chewable tablets - where 2 mg dispersible/ chewable tablets are not marketed and Lamictal 5 mg dispersible/ chewable tablets are the lowest marketed strength: < * If the calculated daily dose in patients taking valproate is 2.5 mg or more but less than 5 mg, then Lamictal 5 mg dispersible/ chewable tablets may be taken on alternate days for the first two weeks.
Hvis den beregnede daglige dosis til patienter, der tager valproat, er lavere end 2, 5 mg, må der ikke administreres Lamictal.
If the calculated daily dose in patients taking valproate is less than 2.5 mg, then Lamictal should not be administered. >
Børn i alderen 2- 6 år vil sandsynligvis have behov for en vedligeholdelsesdosis i den øvre ende af det anbefalede interval.
It is likely that patients aged two to six years will require a maintenance dose at the higher end of the recommended range.
Det skal bemærkes, at det med den aktuelt tilgængelige Lamictal 5 mg dispergible tabletter / tyggetabletter styrke ikke er muligt helt nøjagtigt at initiere behandling med lamotrigin ved brug af de anbefalede retningslinjer for dosering hos børn, der vejer under 17 kg.
5 mg dispersible/ chewable tablets – where 2 mg dispersible/ chewable tablets are not marketed and 5 mg dispersible/ chewable tablets are the lowest marketed strength :< It should be noted that with the currently available Lamictal 5 mg dispersible/chewable tablet strength, it is not possible to accurately initiate lamotrigine therapy using the recommended dosing guidelines in paediatric patients weighing less than 17 kg. >
4. 4).
Children below 2 years There are limited data on the efficacy and safety of lamotrigine for adjunctive therapy of partial seizures in children aged 1 month to 2 years (see section 4.4).
4. 4, 5. 1 og 5. 2.
If, based on clinical need, a decision to treat is nevertheless taken, see sections 4.4, 5.1 and 5.2.
Overgangsregimenet omfatter en gradvis øgning af lamotrigin - dosis til en vedligeholdende stabiliseringsdosis i løbet af seks uger (tabel 3), hvorefter behandling med andre psykofarmaka og/ eller antiepileptika kan seponeres, hvis der er klinisk indikation herfor (tabel 4).
The transition regimen involves escalating the dose of lamotrigine to a maintenance stabilisation dose over six weeks (Table 3) after which other psychotropic medicinal products and/ or AEDs can be withdrawn, if clinically indicated (Table 4).
De dosisjusteringer, der skal foretages efter tilføjelse af andre psykofarmaka og/ eller antiepileptika, er ligeledes anført nedenfor (tabel 5).
The dose adjustments following addition of other psychotropic medicinal products and/ or AEDs are also provided below (Table 5).
4. 4).
Because of the risk of rash the initial dose and subsequent dose escalation should not be exceeded (see section 4.4).
53 Tabel 3:
52 Table 3:
Voksne i alderen 18 år og derover – anbefalet dosisøgning til den samlede daglige vedligeholdende stabiliseringsdosis ved behandling af bipolar sygdom
Adults aged 18 years and above - recommended dose escalation to the maintenance total daily stabilisation dose in treatment of bipolar disorder
25 mg/ dag (én gang dagligt)
Week 5
50 mg/ dag (én gang dagligt eller fordelt på to doser)
Target Stabilisation Dose (Week 6)*
100 mg/ dag (én gang dagligt eller fordelt på to doser)
100 mg/ day
200 mg/ dag – normal måldosis til opnåelse af optimal respons (én gang dagligt eller fordelt på to doser) Doser i intervallet 100 - 400 mg/ dag er anvendt i kliniske forsøg
be used with other medicinal (once a day) products that do not significantly inhibit or induce lamotrigine
Tillægsbehandling MED valproat (hæmmer glukuronidering af lamotrigin – se pkt.
(once a day or (once a day or two divided two divided doses) doses)
4. 5):
glucuronidation
Dette dosisregimen skal
Doses in the range 100 - 400 mg/ day used in clinical trials
12, 5 mg/ dag
This dosage regimen should 12.5 mg/ day
25 mg/ dag
25 mg/ day
50 mg/ dag
50 mg/ day
100 mg/ dag – normal
100 mg/ day - usual target
kombineres med valproat, uanset om der administreres andre lægemidler samtidigt
be used with valproate regardless of any concomitant medicinal products
(administreret som 25 mg hver anden dag)
(given as 25 mg (once a day) (once a day or dose on alternate two divided days) doses)
Der må maksimalt gives en dosis på 200 mg/ dag afhængigt af den kliniske respons
for optimal response (once a day or two divided doses) Maximum dose of 200 mg/ day can be used depending on clinical response
Tillægsbehandling UDEN valproat og MED induktorer af lamotrigin- glukuronidering (se pkt.
Adjunctive therapy WITHOUT valproate and WITH inducers of lamotrigine glucuronidation (see section 4.5):
Dette dosisregimen skal ikke 50 mg/ dag
This dosage regimen should be used without valproate but with:
100 mg/ dag
100 mg/ day (two divided doses)
kombineres med valproat, men med:
200 mg/ day (two divided doses)
(fordelt på to (fordelt på to øgning til den normale doser) doser) måldosis på 400 mg/ dag i uge 7, hvis det er
300 mg/ day in week 6, if necessary increasing to usual target dose of 400 mg/ day in week 7, to
phenytoin carbamazepin phenobarbital primidon rifampicin lopinavir/ ritonavir
phenytoin carbamazepine phenobarbitone primidone rifampicin lopinavir/ ritonavir
nødvendigt, for at opnå den optimale respons (fordelt på to doser)
achieve optimal response (two divided doses)
4. 5), skal der anvendes den dosisøgning, som anbefales for lamotrigin i kombination med valproat.
In patients taking medicinal products where the pharmacokinetic interaction with lamotrigine is currently not known (see section 4.5), the dose escalation as recommended for lamotrigine with concurrent valproate, should be used.
54 Tabel 4:
53 Table 4:
Voksne i alderen 18 år og derover – samlet daglig vedligeholdende stabiliseringsdosis efter seponering af samtidige lægemidler ved behandling af bipolar sygdom
Adults aged 18 years and above - maintenance stabilisation total daily dose following withdrawal of concomitant medicinal products in treatment of bipolar disorder Once the target daily maintenance stabilisation dose has been achieved, other medicinal products may be withdrawn as shown below.
Aktuel stabiliseringsdosis af lamotrigin (før seponering)
Current lamotrigine Week 1 stabilisation dose (beginning with (prior to withdrawal) withdrawal)
Uge 3 og frem *
Week 3 onwards *
4. 5) afhængigt af den oprindelige dosis lamotrigin:
Withdrawal of valproate (inhibitor of lamotrigine glucuronidation – see section 4.5), depending on original dose of lamotrigine:
Når valproat seponeres, skal stabiliseringsdosis fordobles, dog maksimalt med 100 mg/ uge
When valproate is withdrawn, double the stabilisation dose, not exceeding an increase of more than 100 mg/ week
100 mg/ dag
100 mg/ day
200 mg/ dag
200 mg/ day
Oprethold denne dosis (200 mg/ dag) (fordelt på to doser)
Maintain this dose (200 mg/ day) (two divided doses)
300 mg/ dag
300 mg/ day
400 mg/ dag Oprethold denne dosis (400 mg/ dag)
400 mg/ day Maintain this dose (400 mg/ day)
4. 5) afhængigt af den oprindelige dosis lamotrigin:
Withdrawal of inducers of lamotrigine glucuronidation (see section 4.5), depending on original dose of lamotrigine:
Dette dosisregimen skal følges, når følgende midler seponeres:
This dosage regimen should be used when the following are
400 mg/ dag 400 mg/ dag
400 mg/ day 400 mg/ day
300 mg/ dag
300
200 mg/ dag
mg/ day
phenytoin
200 mg/ day
300 mg/ dag 300 mg/ dag
300 mg/ day 300 mg/ day
225 mg/ dag
225
150 mg/ dag
150 mg/ day
carbamazepin phenobarbital primidon rifampicin lopinavir/ ritonavir
phenytoin carbamazepine phenobarbitone primidone rifampicin lopinavir/ ritonavir
200 mg/ dag 200 mg/ dag
200 mg/ day 200 mg/ day
4. 5):
Withdrawal of medicinal products that do NOT significantly inhibit or induce lamotrigine glucuronidation (see section 4.5):
Dette dosisregimen skal følges, når Oprethold den måldosis, der er opnået ved dosisøgning (200 mg/ dag andre lægemidler, der ikke
This dosage regimen should be used when other medicinal products that do not significantly inhibit or induce lamotrigine glucuronidation are withdrawn
signifikant hæmmer eller inducerer (dosisinterval 100- 400 mg/ dag) glukuronidering af lamotrigin, seponeres
Maintain target dose achieved in dose escalation (200 mg/ day; two divided doses) (dose range 100 - 400 mg/ day)
4. 5), skal der anvendes det behandlingsregimen, som anbefales for lamotrigin i kombination med valproat.
In patients taking medicinal products where the pharmacokinetic interaction with lamotrigine is currently not known (see section 4.5), the treatment regimen as recommended for lamotrigine with concurrent valproate, should be used.